Hear from the National Cancer Institute’s Dr. Jay Berzofsky about a new adjuvanted subunit mucosal COVID-19 vaccine. Study results of the vaccine demonstrated that it prevented SARS-CoV-2 transmission and infection. Most SARS-CoV-2 vaccines focus on delivering immunization through an intramuscular injection. This technology combines an initial intramuscular injection with subsequent administration of an intranasal boost of a novel, molecular adjuvant nanoparticle formulation.
This technology is pre-clinical with identified lead compounds. It is patent pending and available for licensing or co-development.
The unique, nanoparticle formulation includes a SARS-Cov-2 spike protein adjuvanted with the combination of TLR agonists CpG & Poly I:C and cytokine IL-15, encapsulated in PLGA or DOTAP nanoparticles. Study results showed that this mucosal vaccine induces robust humoral and cellular immunity, as well as trained innate immunity in vaccinated macaques. Following SARS-CoV-2 intranasal and intratracheal challenges, the vaccinated macaques did not show detectable subgenomic RNA in either of their upper or lower respiratory tracts, compared to naïve controls. Additionally, the vaccinated macaques were more effective at clearing input virus in the nasal mucosa from which it could be transmitted to others. These results demonstrate that this mucosal vaccine can protect against respiratory SARS-CoV-2 exposure and may enhance the protective effect of systemic vaccines, therefore making this new mucosal vaccine a good candidate for a SARS-CoV-2 vaccine.
• Assess co-developing and/or licensing this technology
• Interact with the inventor, ask questions and provide feedback
• Learn how to partner with the NCI
For more information, please contact:
• Jay A Berzofsky, MD, PhD – [email protected]
• Ricquita Pollard, PhD, NCI Technology Transfer Manager – [email protected]
• Wendy Patterson, JD, NCI Technology Transfer Manager – [email protected]